AASLD has published new practice guidance on the clinical assessment and management of NAFLD. Surfers Jörn Schattenberg, Louise Campbell and Roger Green are joined by Ken Cusi to explore its key features and implications which place emphasis on advances in noninvasive risk stratification and therapeutics.
The podcast heads Down Under as Louise Campbell hosts this week’s surf with Brisbane-based guest, Tony Rahman. This final conversation examines Australia’s positioning to distribute limited resources in response to accessing expensive new drugs. As the session winds down, Tony offers his vision for what the next 2-3 years holds for Fatty Liver in Australia.
The podcast heads Down Under as Louise Campbell hosts this week’s surf with Brisbane-based guest, Tony Rahman. In this conversation they explore use of FIB-4 and FibroScan, linking cardiovascular outcomes to Fatty Liver and establishing new systems to improve accessibility of care.
The podcast heads Down Under as Louise Campbell hosts this week’s surf with Brisbane-based guest, Tony Rahman. In this conversation they discuss NAFLD and NASH subpopulations in Australia, and innovative approaches to providing for a large number of rural patients.
The podcast heads Down Under as Louise Campbell hosts this week’s surf with Brisbane-based guest, Tony Rahman. After Tony outlines a career trajectory and how he arrived at the frontlines of NAFLD and NASH in Australia, the duo discuss themes focused around public health and prevalence.
The podcast heads Down Under as Louise Campbell hosts this week’s surf from Australia. Joining her is Brisbane-based Director of Gastroenterology & Hepatology at The Prince Charles Hospital, Tony Rahman. The two discuss NAFLD and NASH prevalence, providing for rural populations, FibroScan, FIB-4 and the future of combating Fatty Liver in Australia.
This episode From the Vault comes from Season 3, Episode 39.4. Ian Rowe’s decision curve model does an excellent job of modeling the success rate and cost effectiveness of modeling early NASH diagnosis. However, as Louise Campbell points out, simply getting the patient diagnosed does not mean therapeutic success, which has implications for the early diagnosis model and broader patient management issues.
Tim Jobson of Predictive Health Intelligence joins the podcast to introduce analyzing historic blood test results to identify those at risk of Fatty Liver disease. In this final conversation, panelists revisit themes of data aggregation, data transparency, patient feedback and more. Surf on to listen to their concluding remarks and learn about the future of the project.
Tim Jobson of Predictive Health Intelligence joins the podcast to introduce analyzing historic blood test results to identify those at risk of Fatty Liver disease. In this conversation, panelists focus on the dual issues of patient data security and proactivity for better health outcomes.
Tim Jobson of Predictive Health Intelligence joins the podcast to introduce analyzing historic blood test results to identify those at risk of Fatty Liver disease. In this conversation, panelists explore various areas of application where the Predictive Health tool may be of significant value.
